Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?
Corpechot C, Lemoinne S, Soret PA, Hansen B, Hirschfield G, Gulamhusein A, Montano-Loza AJ, Lytvyak E, Pares A, Olivas I, Eaton JE, Osman KT, Schramm C, Sebode M, Lohse AW, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo FP, Floreani A, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Sobenko N, Villamil AM, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer AE, Deibel A, Bruns T, Große K, Wetten A, Dyson JK, Jones D, Dumortier J, Pageaux GP, de Lédinghen V, Chazouillères O, Carrat F; Global & ERN Rare-Liver PBC Study Groups. Corpechot C, et al. Among authors: invernizzi p. Hepatology. 2024 Jan 1;79(1):39-48. doi: 10.1097/HEP.0000000000000529. Epub 2023 Jul 3. Hepatology. 2024. PMID: 37399238
A quantitative MRCP-derived score for medium-term outcome prediction in primary sclerosing cholangitis.
Cristoferi L, Porta M, Bernasconi DP, Leonardi F, Gerussi A, Mulinacci G, Palermo A, Gallo C, Scaravaglio M, Stucchi E, Maino C, Ippolito D, D'Amato D, Ferreira C, Nardi A, Banerjee R, Valsecchi MG, Antolini L, Corso R, Sironi S, Fagiuoli S, Invernizzi P, Carbone M. Cristoferi L, et al. Among authors: invernizzi p. Dig Liver Dis. 2023 Mar;55(3):373-380. doi: 10.1016/j.dld.2022.10.015. Epub 2022 Nov 7. Dig Liver Dis. 2023. PMID: 36357293 Free article.
Autoimmune liver diseases.
Scaravaglio M, Carbone M, Invernizzi P. Scaravaglio M, et al. Among authors: invernizzi p. Minerva Gastroenterol (Torino). 2023 Mar;69(1):7-9. doi: 10.23736/S2724-5985.22.03279-X. Minerva Gastroenterol (Torino). 2023. PMID: 36856272 Free article. No abstract available.
Prevalence and significance of antimitochondrial antibodies in autoimmune hepatitis (AIH): Results from a large multicentre study of the International AIH Group.
Gatselis NK, Zachou K, Loza AJM, Cançado ELR, Arinaga-Hino T, Muratori P, Efe C, Floreani A, Invernizzi P, Takahashi A, Takaki A, Beretta-Piccoli BT, van Hoek B, Lytvyak E, Guedes LV, Purnak T, Cazzagon N, Lygoura V, Arvaniti P, Rigopoulou EI, Muratori L, Dalekos GN; International Autoimmune Hepatitis Group. Gatselis NK, et al. Among authors: invernizzi p. Eur J Intern Med. 2023 Oct;116:43-50. doi: 10.1016/j.ejim.2023.06.001. Epub 2023 Jun 10. Eur J Intern Med. 2023. PMID: 37302951
Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, Arrese M, Corpechot C, Francque SM, Heneghan MA, Invernizzi P, Jones D, Kruger FC, Lawitz E, Mayo MJ, Shiffman ML, Swain MG, Valera JM, Vargas V, Vierling JM, Villamil A, Addy C, Dietrich J, Germain JM, Mazain S, Rafailovic D, Taddé B, Miller B, Shu J, Zein CO, Schattenberg JM; ELATIVE Study Investigators’ Group; ELATIVE Study Investigators' Group. Kowdley KV, et al. Among authors: invernizzi p. N Engl J Med. 2024 Feb 29;390(9):795-805. doi: 10.1056/NEJMoa2306185. Epub 2023 Nov 13. N Engl J Med. 2024. PMID: 37962077 Clinical Trial.
Primary Sclerosing Cholangitis and Amyloid A Amyloidosis: Association or Coincidence?
Lacetera R, Roggero L, Vercelloni P, Uzzo M, Carbone M, Invernizzi P, L'Imperio V, Pieruzzi F, Sinico RA. Lacetera R, et al. Among authors: invernizzi p. Case Rep Nephrol Dial. 2022 Oct 4;12(3):178-184. doi: 10.1159/000524665. eCollection 2022 Sep-Dec. Case Rep Nephrol Dial. 2022. PMID: 36518362 Free PMC article.
Corrigendum to: "Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆" [J Hepatol (2020) 505-515].
Anstee QM, Darlay R, Cockell S, Meroni M, Govaere O, Tiniakos D, Burt AD, Bedossa P, Palmer J, Liu YL, Aithal GP, Allison M, Yki-Järvinen H, Vacca M, Dufour JF, Invernizzi P, Prati D, Ekstedt M, Kechagias S, Francque S, Petta S, Bugianesi E, Clement K, Ratziu V, Schattenberg JM, Valenti L, Day CP, Cordell HJ, Daly AK; EPoS Consortium Investigators. Anstee QM, et al. Among authors: invernizzi p. J Hepatol. 2023 May;78(5):1085-1086. doi: 10.1016/j.jhep.2023.02.028. Epub 2023 Mar 13. J Hepatol. 2023. PMID: 36922251 No abstract available.
Predicting de-novo portal vein thrombosis after HCV eradication: A long-term competing risk analysis in the ongoing PITER cohort.
Kondili LA, Zanetto A, Quaranta MG, Ferrigno L, Panetta V, Calvaruso V, Zignego AL, Brunetto MR, Raimondo G, Biliotti E, Ieluzzi D, Iannone A, Madonia S, Chemello L, Cavalletto L, Coppola C, Morisco F, Barbaro F, Licata A, Federico A, Cerini F, Persico M, Pompili M, Ciancio A, Piscaglia F, Chessa L, Giacometti A, Invernizzi P, Brancaccio G, Benedetti A, Baiocchi L, Gentile I, Coppola N, Nardone G, Craxì A, Russo FP; PITER Collaborating Investigators. Kondili LA, et al. Among authors: invernizzi p. United European Gastroenterol J. 2024 Apr;12(3):352-363. doi: 10.1002/ueg2.12496. Epub 2023 Nov 30. United European Gastroenterol J. 2024. PMID: 38032175 Free article.
497 results